Phase-I/II trial of Velcade (bortezomib) in combination with mitoxantrone and etoposide for relapsed or refractory acute leukemias.
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Bortezomib (Primary) ; Cytarabine; Etoposide; Mitoxantrone
- Indications Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2015 Status changed from active, no longer recruiting to completed.
- 07 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 07 Jan 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.